These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 31765922)

  • 1. Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
    Allen JA; Gelinas DF; Freimer M; Runken MC; Wolfe GI
    J Neurol Sci; 2020 Jan; 408():116497. PubMed ID: 31765922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
    Goyal NA; Karam C; Sheikh KA; Dimachkie MM
    Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulatory effects of intravenous and subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: An observational study.
    Svačina MKR; Meißner A; Schweitzer F; Ladwig A; Pitarokoili K; Kofler DM; Sprenger-Svačina A; Schneider C; Kohle F; Klein I; Wüstenberg H; Lehmann HC
    Eur J Neurol; 2024 Jan; 31(1):e16079. PubMed ID: 37789648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
    Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R
    Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective.
    Watkins JM; Dimachkie MM; Riley P; Murphy E
    J Neurosci Nurs; 2019 Aug; 51(4):198-203. PubMed ID: 31107344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgPro20, the Polyneuropathy and Treatment with Hizentra
    Berger M; Harbo T; Cornblath DR; Mielke O
    Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.
    Ness S
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: the ICE trial.
    Hughes RA
    Expert Rev Neurother; 2009 Jun; 9(6):789-95. PubMed ID: 19496683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years.
    Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A
    Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
    Lazzaro C; Lopiano L; Cocito D
    Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous immunoglobulin in responders to intravenous therapy with chronic inflammatory demyelinating polyradiculoneuropathy.
    Markvardsen LH; Debost JC; Harbo T; Sindrup SH; Andersen H; Christiansen I; Otto M; Olsen NK; Lassen LL; Jakobsen J;
    Eur J Neurol; 2013 May; 20(5):836-42. PubMed ID: 23294032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term neurophysiological and clinical response in patients with chronic inflammatory demyelinating polyradiculoneuropathy treated with subcutaneous immunoglobulin.
    Cirillo G; Todisco V; Tedeschi G
    Clin Neurophysiol; 2018 May; 129(5):967-973. PubMed ID: 29554579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
    Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
    PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis.
    Ramzi A; Maya S; Balousha N; Sabet H; Samir A; Roshdy MR; Aljarrah G; Saleh S; Kertam A; Serag I; Shiha MR
    Neurol Sci; 2024 Nov; 45(11):5213-5230. PubMed ID: 38937399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial.
    van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ;
    Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.